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ABSTRACT
Introduction: As a result of the increased use of
radiotherapy (RT) and improved long-term
overall survival of patients with cancers of the
head and neck (HN), the frequency of radiation-
induced sarcomas of the head and neck (RISHN)
may be increasing. The main objective of this
systematic review was to determine the existing
evidence on the frequency, treatment, and
outcome of RISHN.
Methods: Using PRISMA guidelines we con-
ducted a systematic review of the literature
published from 2000 to 2020.
Results: Our review includes data of 560
patients from 64 articles. The total frequency of
RISHNs among the reviewed series was 0.15%.
The most frequent location of the primary
tumor treated by RT was the nasopharynx. The
mean RT dose used was 62 Gy, mean latency
interval between irradiation and occurrence of
RISHN was 11.1 years, and the most common
RISHN location was the sinonasal region.
This article was written by members of the International
Head and Neck Scientific Group (www.IHNSG.com).
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Osteosarcoma was the principal histology, fol-
lowed by fibrosarcoma. Surgery was the most
frequently applied treatment modality. Of all
patients with RISHN, 40.7% died of this disease
after a mean interval of 13.9 months.
Conclusions: Notwithstanding the increased
use of RT, the number of reported RISHNs has
not increased substantially during the past two
decades. Surgery with wide margins forms the
best therapeutic option for these cases, but the
outcome remains poor.
Keywords: Head and neck; Radiation-induced;
Radiotherapy; Sarcoma; Surgical treatment
Key Summary Points
Radiation-induced sarcomas of the head
and neck (RISHN) are a rare but lethal
complication of radiotherapy.
The total frequency among the reviewed
series was 0.15%.
The mean latency interval between
irradiation and occurrence of RISHN was
11.1 years and the most common RISHN
location was the sinonasal region.
Osteosarcoma was the principal histology,
followed by fibrosarcoma. Surgery was the
most frequently applied treatment
modality.
Despite the increased use of radiotherapy,
RISHNs have not increased substantially
during the past two decades. Surgery
forms the best therapeutic option, but the
outcome remains poor.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.13143554.
INTRODUCTION
Radiation-induced sarcomas of the head and
neck (RISHNs) pose a challenging entity in head
and neck (HN) oncology. This tumor appears in
irradiated tissues of the HN without any subsite
predilection [1]. The median latency after
radiotherapy (RT) is reported to be 10–12 years
[2]. The clinical features of RISHNs can be sim-
ilar to other more common RT complications,
like radionecrosis, which makes their diagnosis
difficult in early stages, but sometimes symp-
toms are related to the region where the tumor
appears: diplopia, neck mass, jaw numbness, or
asymmetry in the HN region [3, 4]. The diag-
nostic criteria originally proposed by Cahan and
Woodard [5] and modified by Murray et al. [6]
are still frequently used and include (1) the
tumor arises in a field that has been previously
irradiated, (2) there is evidence that the first
tumor differs histologically from the subse-
quent one, (3) there was no evidence of the new
tumor at the time of RT, and (4) the new tumor
developed after a latency period following RT.
RT has become one of the cornerstones in
the treatment of HN cancer, paralleling an
increase in long-term patient survival [7].
RISHNs are rare tumors, but the population
growth, increased access to and use of RT, the
increasing survival numbers, and advances in
diagnostics have in turn been accompanied by
an obvious increase in the frequency of RISHNs.
In the study by Wei et al., the incidence of
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RISHN increased from 0.06% to 0.17% from
1960 to 2010 at their institution [8].
The most common histologic subtypes are
osteosarcoma, undifferentiated pleomorphic
sarcoma, and fibrosarcoma [9]. They do not
show any subsite predilection and can arise in
any irradiated tissue of mesenchymal origin
within the HN, with most of these tumors being
of high grade [6].
Management of RISHNs remains contro-
versial and all treatment modalities have
been applied: surgery and chemotherapy, but
also re-irradiation and a variety of combina-
tion of these modalities [8]. The overall
prognosis is still poor with a 5-year overall
survival rate varying between 24.2% and
38.2% [4, 10–12].
The main objective of this systematic
review was to determine the existing evidence
on the frequency, treatment, and outcome of
RISHN.
METHODS
The Preferred Reporting Items for Systematic
Review and Meta-Analyses (PRISMA) method
was used to analyze the current literature [13].
The search strategy aimed to include articles
concerning the development of RISHNs in
patients treated with RT. A PubMed search
updated to July 24, 2020 was performed for
publications in English between 2000 and 2020
using the following search criteria in the title or
abstract: ‘‘head and neck’’ coupled with ‘‘radia-
tion induced sarcomas’’, ‘‘radiation associated
sarcomas’’, and ‘‘radiation induced malig-
nancy’’. The search results were reviewed for
potentially eligible studies. When there was any
information in the abstract about the study
addressing RISHNs, the full text article was
searched. All review articles were also screened
to identify reports on these patients. References
from any full text articles were cross-checked to
ensure inclusion of all relevant publications
(Fig. 1). Studies were selected if they met the
Records identified through 
database search
(n = 3299) 
Records excluded
(n = 3176) 
Full-text articles assessed 
for eligibility
(n  = 123) 
Full-text articles 
excluded
(n = 59) 
Articles included in the 
study 
(n = 64) 
Fig. 1 Flowchart showing the study selection process for our systematic review
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following inclusion criteria: (a) patients treated
with RT to their primary tumor, (b) radiation-
induced sarcoma developed in the HN area, and
(c) histological confirmation of the sarcoma has
been obtained. Studies in which the RISHNs
were analyzed together with non-HN radiation-
induced sarcomas were excluded.
The statistical analysis was performed with
SPSS statistical software (IBM SPSS 19.0 Statisti-
cal Software package). The Spearman’s rho cor-
relation coefficient was used for comparison
between the age of the patients and the latency
period to development of the sarcoma. In
addition, differences between mean latency
times by age group were analyzed using the
analysis of variance (ANOVA) test. P values of
0.05 or less were considered statistically
significant.
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
RESULTS
Our search criteria identified 3299 papers and,
after removal of duplicates and those that did
not meet our inclusion criteria, 64 were selected
for data review as summarized in Table 1
[1, 3, 4, 8, 10–12, 14–70]. Most papers were
excluded because they involved radiation-in-
duced sarcomas outside the HN area. Our review
includes 560 patients with 561 RISHNs (one
patient had two simultaneous tumors) from 64
articles during a period of 20 years (2000–2020).
Some of the parameters addressed were not
available in all studies. There were 363 men and
179 women (male-to-female ratio, 2:1). The
most frequently reported location of the pri-
marily treated tumor was the nasopharynx (368
cases, or 65.7%), followed by the sinonasal
region (21 cases, or 3.7%), central nervous sys-
tem (19 cases, or 3.4%), eye (14 cases, or 2.5%),
and larynx (13 cases, or 2.3%). The mean RT
dose prescribed to the primary tumor was 62 Gy
(range 36–101). RISHNs most frequently
appeared in the sinonasal region (33.7%), fol-
lowed by the mandible and the neck (15.9%
and 13.4%, respectively). The most common
histologies were osteosarcoma (35.5%) and
fibrosarcoma (23%). The median age at diag-
nosis of RISHN was 52 years (interquartile range
21.5) and the mean latency between the initial
RT treatment and the diagnosis of RISHN was
11.1 years (range 1.3–38). The mean age at the
treatment of the primary tumor was 43.1 years
(range 2–81), but still only 37.5% of the patients
had a mean age of less than 40 years. Most of
the patients (62.5%) in our review had a mean
age of 40 years or older when they were treated
for the primary tumor with RT. This leads us to
think that RISHNs are less frequent in young
patients who are treated with RT. In order to
investigate if age at the time of the primary RT
treatment is related to latency time, we ana-
lyzed these two groups separately, i.e., patients
under 40 years old and patients older than
40 years. In the group of patients under 40 years
of age, the mean age was 26 years (range 2–38.6)
with a mean latency until diagnosis of the sar-
coma of 14.1 years (range 2.3–38). On the other
hand, in the group of patients aged older than
40 years, the mean age was 55.1 years (range
40–81) and a mean latency until appearance of
the sarcoma of 9.6 years (range 1.3–22).
The Spearman’s rho correlation coefficient
was used for comparison between these two
groups. The result was that there is an inverse
correlation (q = -0.423) between age at the
primary RT treatment and latency time, and
this result was statistically significant
(P = 0.001). So, the older the patient, the
shorter the latency period. Differences between
mean latency times in these two age groups
were analyzed using the ANOVA test, and the
result was that the latency time is greater in
patients under 40 years of age and the differ-
ence is statistically significant (P = 0.01).
Therefore, older patients treated with RT
develop the sarcoma sooner after treatment
than younger patients.
The most frequently used treatment modal-
ity was surgery (45.1%), and less commonly
multimodal treatment (24.1%). Chemotherapy
or RT alone were used less often (8.9% and
5.2%, respectively) and these modalities were
mostly applied as palliative treatment. A total
number of 228 patients died of the RISHN


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(range 3–48) after the diagnosis of RISHN. There
was a large number of patients for whom sur-
vival data were not available (173 cases, 30.9%).
Ninety-five patients (17%) were alive without
known disease with a mean survival time of
32.9 months (range 4–120). For patients alive
with disease the mean survival was 31.2 months
(range 7–54). In total, 4.5% of the patients died
from intercurrent disease. In order to know if
the results of the treatment of these patients
have varied over the years because of the
advances that have been experienced both in
surgery and in oncological treatments, we divi-
ded the reviewed articles into two groups
according to the year when they were pub-
lished: 2000–2010 and 2011–2020. In the
2000–2010 group, the patients died of disease
after a mean time period of 13.5 months (range
3–48), and the mean follow-up time for those
alive with no evidence of disease was
36.3 months (range 12–83), and for those alive
with disease it was 46.4 months (range 28–54).
In the 2011–2020 group, the patients died of
disease after a mean survival time period of
13.9 months (range 3–48), the mean follow-up
time for those alive with no evidence of disease
was 29.2 months (range 4–120), and for those
alive with disease it was 12.2 months (range
7–17). Therefore, it seems that the mean life
expectancy for those patients dying of RISHN
has remained practically the same in the articles
published during the past two decades. The
follow-up times for the patients alive were
longer in the earlier group and thus no con-
clusions can be drawn regarding their results.
The frequency of reported RISHNs in the
published series is given in Table 2. In total,
there were 252 RISHNs among 168,115 patients
who had been treated with RT, with a mean
frequency of 0.15%. It should be noted that this
frequency in the present systematic review is
reported according to the date of publication of
the reviewed articles, i.e., between 2000 and
2020. However, the included patient series in
these reviews cover much longer period,
specifically from 1964 to 2015.
DISCUSSION
RISHNs remain a rare late complication of RT,
and typically occur between 10 and 12 years
after RT [2]. The effectiveness of RT for treat-
ment of cancers and its increasingly widespread
use have led to a parallel surge in adverse effects
arising from it. This rise may be also due to the
higher long-term survival rate generally
observed in HN cancers (owing to early diag-
nosis, improved oncological and surgical tech-
niques, and the use of systemic therapy), and
the use of higher RT doses [3, 8]. In the present
review, we found a frequency of 0.15% for
RISHNs in the series published during the two
past decades. The significance of this finding
remains questionable, as only eight series with
252 patients were included, although the whole
cohort having received RT in the included
reports was rather representative with 168,115
patients.
The exact etiology of RISHNs remains
unknown, but radiation likely induces their
development by causing damage to DNA within
the cells [3]. There is no safe threshold in terms
of RT dose, below which there is no risk of
Table 2 Frequency of RISHNs in the published series







Xi et al. 2010 [10] 39,118 53 0.13
Kunert et al. 2012
[51]
433 1 0.2
Wei et al. 2012 [8] 16,634 17 0.1
Cai et al. 2013
[53]
22,386 59 0.26
Liao et al. 2016
[63]
53,760 45 0.08






Total 168,115 252 0.15
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causing a second tumor [2]. The results of some
studies indicated that the risk of developing
RISHN increases with accumulated radiation
dosage [71]. More specifically, in one study a
total dose higher than 30 Gy increased the risk
of developing RISHN [72]. As we included only
patients treated with curative intent, the mean
RT dose received for treating the primary tumor
was 62 Gy (range 36–101) and thus these
patients were considered at risk for developing
RISHN. We are aware that sarcomas sometimes
appear in areas of medium dose within the
primary RT field, so the dose received in the
primary tumor may not be as important as the
dose delivered in the area where the sarcoma
appears. Unfortunately, these data are usually
not available in the published articles, and
instead only the mean dose is reported.
The age range of patients with RISHNs varied
among studies, but usually occurs between the
6th and 7th decade of life [1, 6, 8]. We found
that the median age at diagnosis was 52 years
(interquartile range 21.5), which is in line with
what has been published previously.
The mean latency period in our review was
11.1 years, but with a wide range (1.3–38 years),
possibly because there are many single cases
published. In the past, the latency time factor
was used to differentiate radiation-induced sar-
comas from de novo sarcomas, but now most
studies do not take that time period into con-
sideration and those that occur with short
latency periods are included as radiation-in-
duced sarcomas, since they are impossible to
differentiate [12]. There are studies demon-
strating a shorter latency period (between 7.7
and 9.3 years) than the one reported in our
review (11.1 years), but the mean age in these
series was almost 50 years. This is in accordance
with the latency period of 9.6 years for the
patients over the age of 40 years in the present
review [8, 10].
The location of the RISHN depends essen-
tially on the location of the primary tumor.
Nasopharyngeal cancer irradiation was typical
in the present review and has been reported
earlier [66] and consequently the most common
site of RISHN being the paranasal sinuses.
Sinonasal tract, central nervous system, eye,
and larynx were frequent primary tumor sites as
well among the present studies.
With regard to the different histological
RISHN subtypes that can be observed, the fol-




domyosarcoma, spindle cell sarcoma, and oth-
ers [3]. Cai et al. [53] found that the most
common histologies were fibrosarcoma (44.1%)
and osteosarcoma (30.5%). Zhu et al. [3] found
osteosarcoma to be the most common histology
(34.1%), followed by fibrosarcoma (19.2%) and
undifferentiated pleomorphic sarcoma (15.8%).
In the study by Thiagarajan and Gopalakrishna
Iyer [9], undifferentiated pleomorphic sarcoma
was the most frequent histology. In our study,
the most frequently encountered histologic
types were osteosarcoma (35.5%) and fibrosar-
coma (23%), which is in line with some of the
previously published studies. Less common
were undifferentiated pleomorphic sarcoma
(13%) and sarcomas not otherwise specified
(10.2%).
Treatment of RISHN varied widely between
the studies. In our review, almost half of the
patients received surgical treatment (45.1%)
when the lesion was resectable. Other modali-
ties, like RT or chemotherapy alone or multi-
modality treatment, were used less commonly.
As RISHNs are rare tumors, with varying his-
tologies at different locations and the available
knowledge being based on retrospective studies,
it is difficult to define clear recommendations
for their treatment. As RISHNs most frequently
occur in previously irradiated areas that
received a high dose, surgery remains the pre-
ferred treatment modality in case RISHN is
considered resectable. Adequate surgical mar-
gins are difficult to achieve, and this is even
more difficult when neighboring vital structures
and the previous RT-induced fibrous transfor-
mation of tissues with impaired blood flow
further complicate surgery and increase com-
plication rates [73]. In unresectable cases,
definitive radiotherapy alone or combined with
systemic treatment may be considered but is
generally associated with a high risk of severe
radiation-induced side effects and, furthermore,
Adv Ther
there have been no advances in terms of effec-
tive systemic therapies. According to some
authors, chemotherapy will be less effective in
radiation-induced sarcomas compared with de
novo sarcomas because of fibrotic changes in
the previously irradiated field and, conse-
quently, impaired vascularity thus impeding
chemotherapeutic agents from reaching ade-
quate concentrations in the target area [16], but
the evidence for this is lacking.
Cha et al. [73] reviewed the results obtained
by surgical resection of RISHNs and found that
the 1-year, 3-year, and 5-year overall survival
rates were 78%, 58%, and 41%, respectively,
with a median survival of 48 months. The
3-year overall survival rate reported by Xi et al.
[10] was 32.4% and the 5-year overall survival
rate reported by Chan et al. [11] was 24.2%. For
Yeang et al. [12] the 2-year and 5-year overall
survival rates were 57.3% and 38.2%, respec-
tively. Unfortunately, overall survival data were
not available in most of the studies in this
review, given the large number of included case
reports.
CONCLUSION
Our review represents the most comprehensive
systematic analysis of RISHNs to date, collecting
data from 560 patients. Most of the included
studies were case reports or only comprised a
few cases. We herein emphasize that RISHNs are
a rare but lethal complication of RT. The fre-
quency has remained rather stable. Surgery with
free margins remains the treatment option of
choice for RISHNs. However, given the location
of the tumor, this may be difficult to achieve in
some cases.
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